MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective

Leonard H Verhey1, Helen M Branson, Manohar M Shroff

  • 1Neurosciences and Mental Health, Research Institute, The Hospital for Sick Children, University of Toronto, ON, Canada.

The Lancet. Neurology
|November 10, 2011
PubMed

Insights

Specific MRI features, including T1-weighted hypointense and periventricular lesions, can predict multiple sclerosis (MS) in children with CNS demyelination. Early identification of pediatric MS improves care and aids clinical trials.

Area of Science:

  • Neurology
  • Radiology
  • Pediatrics

Background:

  • Pediatric demyelinating CNS events require accurate diagnosis to differentiate multiple sclerosis (MS) from other conditions.
  • MRI features are crucial for diagnosing MS in adults, but specific predictors in children are less defined.

Purpose of the Study:

  • To identify standardized MRI predictors for diagnosing pediatric multiple sclerosis (MS) in children experiencing acute central nervous system (CNS) demyelination.

Main Methods:

  • A standardized scoring method was developed and applied to MRI scans from a national prospective cohort of children with CNS demyelination.
  • Baseline MRI scans were analyzed for 14 binary parameters, with univariate and multivariable Cox proportional hazards models used to identify MS predictors.

Main Results:

  • Of 284 participants followed for nearly 4 years, 57 (20%) were diagnosed with MS.
  • The presence of T1-weighted hypointense lesions (HR 20.6) or periventricular lesions (HR 3.34) significantly increased the likelihood of MS diagnosis.
  • The combination of both lesion types yielded the highest risk (HR 34.27), with high sensitivity (84%) and specificity (93%) for MS prediction.

Conclusions:

  • Specific MRI parameters, particularly T1-weighted hypointense and periventricular lesions, can reliably predict MS in children with incident CNS demyelination.
  • Prompt identification of pediatric MS through these MRI markers facilitates timely access to care and supports future clinical trial development.
Abstract